Glaxo Wellcome, the UK pharmaceuticals company, presented clinical trial data for abacavir, an HIV drug submitted last week to US, Canadian and European authorities for approval. Glaxo, which was promoting its compound at the 12th World AIDS Conference in Geneva, hopes the US Food and Drug Administration will approve abacavir by the end of the year.